What endometriosis is
Endometriosis happens when tissue similar to the lining of the uterus grows outside the uterus, most often on the ovaries, fallopian tubes and the tissues that hold the uterus in place. The Office on Women’s Health says researchers think at least 11% of women have it, and that it is especially common in women in their 30s and 40s. Pain is the most common symptom: very painful menstrual cramps, long term pelvic or lower back pain, pain during or after sex, intestinal pain, and painful bowel movements or urination during periods. It can also make it harder to get pregnant.
There is no cure, but treatments are available for the symptoms. For people not trying to get pregnant, hormonal birth control is generally the first step, including extended cycle or continuous pills, the shot or a hormonal IUD.
Do GLP-1 medications treat endometriosis?
No. No GLP-1 medication is FDA approved to treat endometriosis, and we found no clinical trial testing one for it. Wegovy® (semaglutide) and Zepbound® (tirzepatide) are approved, with a reduced calorie diet and more physical activity, for weight reduction in adults with obesity, or with overweight and at least one weight related health condition.
You may see headlines suggesting otherwise. Those come from laboratory research and theory, not from trials in patients. A 2022 study of 54 women with endometriosis found lower GLP-1 levels in the fluid around the pelvic organs than in a comparison group, which the authors suggested might play a role in the condition. A 2026 paper proposed that tirzepatide could in theory act on inflammation and pain pathways in endometriosis, and stated plainly that its idea rests largely on indirect evidence, that direct clinical validation is absent, and that it is not evidence of benefit.
So if you have endometriosis, any GLP-1 prescription would be for weight, and endometriosis would be one part of your health history your provider considers.
The birth control warning that matters here
Because hormonal birth control is so often part of endometriosis care, one label instruction deserves attention. The Zepbound® and Mounjaro® labels say tirzepatide may make birth control pills less effective, because it slows how quickly the stomach empties. The effect is largest after the first dose and lessens over time. The labels advise switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. They also say hormonal birth control that is not taken by mouth should not be affected.
This pertains to the brand name only. You cannot compare the personalized compounded version to this study because it is a different product entirely. For personalized compounds, the medical provider should be consulted.
If you take a pill for endometriosis, it may be doing two jobs, preventing pregnancy and managing symptoms. Tell both your GLP-1 provider and the provider who treats your endometriosis exactly what you take, so they can agree on a plan together. Do not stop or change a hormonal medicine on your own.
Telling symptoms apart
Endometriosis can cause intestinal pain and painful bowel movements. GLP-1 medications cause digestive effects too: the Zepbound® label lists nausea, diarrhea, vomiting, constipation and abdominal pain among its most common side effects, and the Wegovy® label lists similar effects. That overlap can make it hard to know what is causing what.
Both labels also warn about acute pancreatitis. The Zepbound® label says its signs may include persistent or severe abdominal pain, sometimes spreading to the back, with or without nausea or vomiting. Both labels also warn about gallbladder problems.
This pertains to the brand name only. You cannot compare the personalized compounded version to this study because it is a different product entirely. For personalized compounds, the medical provider should be consulted.
Keeping a simple log of when pain happens, where it is, and how it lines up with your cycle and your dose days can help your providers sort it out. Severe abdominal pain that does not go away needs a call to your provider right away.
Endometriosis, weight and fertility
Researchers have noticed that endometriosis is diagnosed less often in people with a higher body weight. A 2026 review cautions that this may be a correlation rather than a cause, and suggests part of it may come from how pain and appetite changes delay diagnosis, and from how body size can make surgery to diagnose it harder. In other words, weight does not cause or prevent endometriosis in any way that has been proven.
If you are trying to get pregnant, tell your provider before starting treatment. The Wegovy® label says to stop it at least 2 months before a planned pregnancy, and the Zepbound® label says to stop it when pregnancy is recognized.
This pertains to the brand name only. You cannot compare the personalized compounded version to this study because it is a different product entirely. For personalized compounds, the medical provider should be consulted.
What this means for a compounded prescription
The label instructions above come from studies of Wegovy®, Zepbound® and Mounjaro®, and personalized compounded semaglutide and tirzepatide are not FDA-approved and were not studied in those trials.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
Share your endometriosis diagnosis, your hormonal treatment and your pregnancy plans with your provider. Dosing, stopping and switching are always your provider’s decision.
